MedTrace Logo

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus.

PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have undergone donor stem cell transplant and have cytomegalovirus infections.

Conditions

Interventions

BIOLOGICAL

cytomegalovirus IE-1-specific cytotoxic T lymphocytes

BIOLOGICAL

cytomegalovirus pp65-specific cytotoxic T lymphocytes

BIOLOGICAL

therapeutic allogeneic lymphocytes

GENETIC

polymerase chain reaction

OTHER

flow cytometry

OTHER

immunological diagnostic method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Kenneth G. Lucas, MD · Milton S. Hershey Medical Center

Study Design

Purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00769613 on ClinicalTrials.gov